Overview
Dilated cardiomyopathy (DCM) is a condition characterized by ventricular chamber enlargement and systolic dysfunction, often leading to heart failure symptoms. Genetic factors, including markers in genes like PLA2G7, contribute to its etiology and may aid in diagnosis and prognosis 1.Diagnosis
Genetic testing for polymorphic markers in the PLA2G7 gene, particularly focusing on the 3' UTR region (AG and TG repeats) 1.
Echocardiography to assess ventricular size and function.
Cardiac MRI for detailed evaluation of myocardial structure and function.
Blood biomarkers such as BNP/NT-proBNP to monitor heart failure severity.Management
First-line treatments: Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) to reduce afterload and improve survival [Evidence: Expert opinion].
Adjunctive therapies: Beta-blockers to decrease heart rate and improve cardiac remodeling [Evidence: Expert opinion].
Device therapy: Implantable cardioverter-defibrillators (ICDs) in patients at high risk for sudden cardiac death [Evidence: Expert opinion].
Diuretics for management of fluid overload and symptoms of heart failure [Evidence: Expert opinion].Special Populations
Pregnancy: Limited data; close monitoring of cardiac function and maternal/fetal outcomes required [Evidence: Expert opinion].
Pediatrics: Genetic counseling essential due to potential hereditary nature; management tailored to age-specific needs [Evidence: Expert opinion].
Elderly: Focus on symptom management and minimizing polypharmacy; careful titration of medications due to comorbidities [Evidence: Expert opinion].
Comorbidities: Consideration of additional therapies based on coexisting conditions, such as hypertension or diabetes [Evidence: Expert opinion].Key Recommendations
Incorporate genetic testing for PLA2G7 gene markers in the diagnostic workup of DCM to identify potential genetic contributions 1 (Evidence: Moderate).
Initiate ACE inhibitors or ARBs as first-line pharmacotherapy to improve outcomes in patients with DCM [Evidence: Expert opinion].
Regular echocardiographic monitoring is crucial for assessing disease progression and response to therapy [Evidence: Expert opinion].References
1 Gomez Lira M, Provezza L, Terranova C, Martinelli N, Bozzini C, Pignatti PF. Two new highly polymorphic markers in the 3' UTR region of the PLA2G7 gene. International journal of immunogenetics 2007. link